10 results about "Calcium oxalate calculus" patented technology

The invention relates to the field of microorganisms, in particular to cat-source lactobacillus plantarum capable of degrading oxalic acid and application of the cat-source lactobacillus plantarum, the preservation number of the cat-source lactobacillus plantarum is CGMCC NO.35212, and the cat-source lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center. The cat-derived lactobacillus plantarum has degradation capability on oxalic acid, has relatively strong acid resistance and cholate resistance, has a good inhibition effect on common pathogenic bacteria, is sensitive to various antibiotics and has good probiotic practical potential, and a new candidate strain is provided for pet food, health-care treatment products or probiotic preparations. In addition, the strain has a potential effect of preventing and treating calcium oxalate calculus, and has a wide prospect in the aspects of preparation of pet food, health care products, probiotic preparations, medicines and the like.

The invention belongs to the field of pet food processing, and relates to a premix for improving the health of urinary tracts of pets. The premix comprises the following components in parts by weight: 25-35 parts of Chinese yams, 25-35 parts of poria cocos, 15-25 parts of dandelions, 15-25 parts of centella asiatica, 15-25 parts of semen plantaginis, 5-15 parts of rhizoma polygonati, 5-15 parts of dogwood and 5-15 parts of Chinese wolfberry fruits. By adding the premix disclosed by the invention into daily ration, the concentrations of cat blood creatinine, urea nitrogen and blood oxalic acid are reduced, the absorption and excretion of oxalic acid are influenced, and the formation of calcium oxalate calculi is prevented. The premix disclosed by the invention can relieve the kidney toxicity of sodium oxalate to cats, improve the physiological indexes of the kidneys, reduce the formation of calcium oxalate calculi and provide basic guarantee for the treatment of chronic urinary system diseases. The premix disclosed by the invention can be used for improving the urinary tract health of cats.

This patent document discloses novel oxamaies that can act as potent inhibitors of calcium oxalate (CaOx) crystallization and new macrocyclic prodrugs that will offer improved lipophilicity, small size, lower polar surface area, and greatly reduced solvent accessible surface area, all properties known to impart better oral bioavailability. Also disclosed herein are methods of treating diseases associated with abnormal levels of calcium oxalate and its crystallization.

The invention belongs to the technical field of kidney stone examination. The invention relates to the field of biotechnology, in particular to application of Allobacter as a microbial marker in preparation of a product for diagnosing kidney calcium oxalate calculus, and particularly relates to application of Allobacter as a microbial marker in preparation of a product for diagnosing kidney calcium oxalate calculus. According to the present invention, the research results show that the Allobacter microorganism can be adopted as the potential biomarker for the diagnosis of the kidney calcium oxalate calculus; the scheme can be used for assisting clinical diagnosis of kidney calcium oxalate calculi and screening of high-risk people, and a brand new thought and an effective means are provided for accurate prevention and control of kidney calcium oxalate calculi. The invention provides a novel and noninvasive microbial marker which is used for auxiliary diagnosis of kidney stone. The marker has good detection specificity and high sensitivity, can effectively reflect the occurrence and development conditions of calcium oxalate calculi, is expected to replace a traditional imaging examination method, realizes simple, convenient and rapid diagnosis of urinary calculi, and has good application prospects and values.

The present invention discloses a class of citric acid series carbon dots and their application in the preparation of calcium crystal inhibitors. The citric acid series carbon dots are carbon dots obtained by chemically synthesizing citric acid series substances. The citric acid series carbon dots of the present invention have the advantages of good water solubility, good stability, low biological toxicity, and renal clearance. Therefore, they can replace common organic small molecule acids with poor stability, high biological toxicity, and difficult metabolism to regulate the crystallization process of calcium oxalate crystals. Such carbon dots can not only promote the transformation of calcium oxalate monohydrate crystals into calcium oxalate dihydrate crystals that are easier to excrete from the body, but also inhibit the growth of calcium oxalate crystals, reducing their average crystal grain size by 20%. At the same time, through the renal clearance mechanism of carbon dots, the fluorescence in urine can be used to study their metabolism in the body. Such carbon dots show great application potential in the treatment of calcium oxalate stones.

The invention relates to a composition for preventing or treating calcium oxalate kidney stone and application thereof. The invention particularly relates to a composition for preventing or treating calcium oxalate kidney stone, which comprises hydroxymalonic acid, 2, 3-diaminophenazine and a liposome carrier. The composition disclosed by the invention can be used for systematically intervening a core link of the calcium oxalate calculus and is effectively used for preventing and treating the calcium oxalate calculus.

The application discloses a protein UP5 of the Malpighian tubule of Euproctis pseudoconspersa and application thereof, the protein can be combined with calcium ions, and has a significant ability of inhibiting formation of calcium oxalate crystals, and can be used for preventing and treating calcium oxalate stones which are the most common kidney stones, so that a new strategy for treating kidney stones is expected to be provided, and the protein UP5 of the Malpighian tubule of Euproctis pseudoconspersa provides a new drug use.

This invention belongs to the field of pet food processing and relates to a premix for improving the urinary tract health of pets. The premix contains the following components in parts by weight: 25-35 parts of Dioscorea opposita, 25-35 parts of Poria cocos, 15-25 parts of Taraxacum mongolicum, 15-25 parts of Centella asiatica, 15-25 parts of Plantago asiatica, 5-15 parts of Polygonatum sibiricum, 5-15 parts of Cornus officinalis, and 5-15 parts of Lycium barbarum. Adding this premix to the cat's diet reduces serum creatinine, blood urea nitrogen, and serum oxalate concentrations, affecting oxalate absorption and excretion, and preventing the formation of calcium oxalate stones. This premix can alleviate the nephrotoxicity of sodium oxalate in cats, improve renal physiological indicators, reduce the formation of calcium oxalate stones, and provide a basic guarantee for the treatment of chronic urinary system diseases. This premix can improve the urinary tract health of cats.

The present invention discloses the use of terminalia chebula acid in the preparation of a drug for treating urinary stones. Terminalia chebula acid is an organic acid containing three carboxyl groups (‑COOH) and three hydroxyl groups (‑OH) in its molecular structure. The coordination bond between the carboxylate ion of terminalia chebula acid and the calcium ion can effectively fix the calcium ion to form a soluble complex. The present invention found that terminalia chebula acid at an appropriate concentration or dose showed a good effect in inhibiting the formation of renal calcium oxalate stones. In addition, terminalia chebula acid at an appropriate dose or concentration can significantly alleviate the damage and resulting apoptosis of renal tubular HK‑2 cells caused by oxalic acid and kidney stones.

This invention provides the application of an S100A6 inhibitor in the preparation of a drug for treating calcium oxalate stones. This invention is the first to discover that S100A6 plays a crucial role in the formation of calcium oxalate stones. It promotes STAT3 phosphorylation, upregulates the expression of NADPH oxidase subunits p67phox and p40phox, promotes reactive oxygen species (ROS) generation, and induces autophagy and apoptosis in renal epithelial cells, thereby promoting calcium oxalate stone formation. Furthermore, the S100A6 small molecule inhibitor AP-048 provided by this invention specifically binds to S100A6. In vitro and in vivo experiments have confirmed that AP-048 can significantly inhibit calcium oxalate crystal cell adhesion, reduce ROS levels, decrease renal crystal deposition, alleviate renal tubular damage and inflammatory factor expression, and has no significant hepatotoxicity or nephrotoxicity. This invention provides a new target and therapeutic strategy for calcium oxalate stones, with promising clinical application prospects.